SecBot SecBot
SECBOTREPLAY Home › Report › PYXS

PYXS · Pyxis Oncology appointed interim CEO Thomas Civik as permanent CEO and…

Pyxis Oncology, Inc. · 8-K filed Sep 8, 2026 at 07:39 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Sep 8, 2026 at 07:39 ET

Pyxis Oncology appointed interim CEO Thomas Civik as permanent CEO and Chairman, replacing John Flavin who becomes Lead Independent Director. Board member Dr. Santhosh Palani resigned. The filing is a routine leadership transition with no material financial data, the company remains a clinical-stage biotech awaiting key MICVO data readouts in Fall 2026 and Q4 2026.

  • Thomas Civik appointed permanent CEO and Chairman, effective September 4, 2026, after serving as interim CEO since February 2, 2026.
  • John Flavin transitions from Chairman to Lead Independent Director and Chair of Compensation Committee.
  • Dr. Santhosh Palani resigned from the Board effective September 4, 2026, citing increased time commitments; Board reduced from 8 to 7 members.
  • Civik receives $710,000 annual base salary, 60% target bonus, $100,000 sign-on bonus, and a nonqualified stock option for 2,503,050 shares.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access